Connect with us

Health

ANC: Why pregnant women with non-communicable diseases should register in teaching hospitals

Published

on

ADVERTISEMENT
Zoom Ad
ADVERTISEMENT
Zoom Ad

By Francesca Hangeior

Maternal health experts have advised pregnant women with non-communicable diseases such as heart disease, hypertension, diabetes, and sickle cell disorder to register for antenatal care in teaching hospitals where they can get specialist care.

The gynaecologists noted that pregnancy among women with these health conditions was associated with high risk, especially during delivery, and therefore should be managed where there are specialists to avoid losing the baby or the mother or both.

The experts reiterated that pregnant women with those conditions needed to use tertiary hospitals for their ANC to reduce complications during and after birth.

Advertisement

A Consultant Obstetrician and Gynaecologist at the Nnamdi Azikiwe Teaching Hospital, Akwa, Anambra State, Dr. Stanley Egbogu, said pregnancy among women with co-morbidities comes with concern and lots of complications.

Egbogu said, “Women who have diseases like hypertension, diabetes, and heart disease before pregnancy must not use primary health centers for their antenatal care.

” It is important they register in a teaching or specialist hospital for their antenatal care because they need specialized care by experienced obstetricians and gynaecologists.

“If such women should visit PHCs for antenatal care, they should be referred to a teaching hospital immediately because they are prone to so many complications during pregnancy.”

Advertisement

The gynaecologist noted that people with hypertension could convulse during pregnancy.

“Those who have diabetes can have renal failure during pregnancy and delivery.

Those who have sickle cell disease can have anemia, and their blood can be so low that many of them have issues during delivery. For those who are asthmatic, pregnancy can worsen the asthmatic condition, and some of the drugs they use can affect the baby if not monitored.

“So, these women need specialised care and that cannot be offered at the primary healthcare level. The truth is that if those complications are not effectively managed, they could lead to the death of the woman or her baby”, he said.

Advertisement

Egbogu also advised the women to start antenatal care early and be regular at the antenatal clinic because “we want to see those that have problems more often than those that do not have problems.”

The Centres for Disease Control and Prevention says a woman with sickle cell disease is more likely to have problems during pregnancy that can affect her health and the health of the unborn baby than a woman without the disease.

During pregnancy, the disease can become more severe, and pain episodes can occur more often. A pregnant woman with SCD is at a higher risk of preterm labor, having a low birth weight baby, or other complications. However, with early prenatal care and careful monitoring throughout pregnancy, a woman with SCD can have a healthy pregnancy”, the CDC said.

According to the Asthma and Allergy Foundation of America, about 30 percent of all women with asthma report their asthma worsened while pregnant.

Advertisement

The foundation notes “Pregnant women with asthma may have a bit greater risk of delivering early. Or the infant may have a low birth weight. High blood pressure and a related condition known as pre-eclampsia are also more common in pregnant women with more severe asthma.”

Another maternal health expert and a Senior Registrar in the Obstetrics and Gynaecology Department at the Aminu Kano Teaching Hospital, Kano State, Dr. Mahmoud Magashi, says it is better and safer for pregnant women with co-morbidities to deliver in a specialist hospital to effectively manage associated risks both during and after delivery.

According to the World Health Organisation, in 2015, Nigeria’s estimated maternal mortality ratio was over 800 maternal deaths per 100,000 live births, with approximately 58,000 maternal deaths during that year.

But the Demographic and Health Survey 2018 showed that Nigeria’s latest maternal mortality ratio is 512 per 100,000 live births, which experts say is still very high.

Advertisement
Continue Reading
Advertisement
Click to comment

Warning: Undefined variable $user_ID in /home/naijuinz/public_html/wp-content/themes/zox-news/comments.php on line 49

You must be logged in to post a comment Login

Leave a Reply

Health

NAFDAC Blacklists Onifam Laboratories, Directors Over Regulatory Infractions

Published

on

By

ADVERTISEMENT
Zoom Ad
ADVERTISEMENT
Zoom Ad

The National Agency for Food and Drug Administration and Control (NAFDAC) has blacklisted Onifam Laboratories Limited, its Managing Director/Chief Executive Officer, all members of its board of directors, and every affiliated or associated individual and entity found to have participated in regulatory violations, following what it described as extensive investigations into the company’s operations.

The sanction, which takes immediate effect, effectively excludes the company and all affected individuals from participating in any pharmaceutical business regulated by NAFDAC pending further directive from the agency.

In a statement signed on Monday by its Director-General/CEO, Prof. Mojisola Adeyeye, the agency said its investigations established that Onifam Laboratories engaged in regulatory misrepresentation, misuse of NAFDAC approvals and certificates, improper registration and transfer of pharmaceutical products, as well as activities that deliberately circumvented established regulatory procedures.

According to NAFDAC, the alleged infractions compromise product traceability, weaken accountability within the pharmaceutical supply chain and expose the public to significant health risks.

Advertisement

The agency said the company’s actions violate the provisions of the NAFDAC Act, the Food, Drug and Related Products (Registration, etc.) Act, the Drug and Related Products Registration Regulations 2021 and other applicable regulatory guidelines governing pharmaceutical products in Nigeria.

As part of the blacklist, Onifam Laboratories and all affected persons are prohibited from participating, either directly or indirectly, in any pharmaceutical business regulated by NAFDAC.

The prohibition extends to applying for or benefiting from any NAFDAC registration, licence, permit, certificate or approval.

It also bars them from operating as manufacturers, importers, distributors, marketing authorisation holders, agents, representatives, consultants, promoters or sponsors of any product regulated by the agency.

Advertisement

Prof. Mojisola Adeyeye, Director-General/Chief Executive Officer of the National Agency for Food and Drug Administration and Control (NAFDAC), whose agency announced the immediate blacklisting of Onifam Laboratories Ltd, its Managing Director, directors and affiliated entities over multiple regulatory violations/Credit: NAFDAC

The sweeping sanctions equally apply to affiliated companies and associated entities found to have been involved in the regulatory violations.

NAFDAC stated that the blacklist would remain in force until otherwise directed by its management.

The agency further warned that it reserves the right to initiate additional regulatory, administrative, enforcement and legal actions where necessary to protect public health and preserve the integrity of Nigeria’s medicines regulatory system.

Advertisement

It stressed that the action reflects its determination to ensure strict compliance with pharmaceutical regulations and deter practices capable of undermining the safety and quality of medicines available to Nigerians.

Reaffirming its commitment to safeguarding public health, NAFDAC urged all stakeholders in the pharmaceutical sector to comply fully with applicable laws and regulatory requirements.

The agency maintained that only safe, quality-assured and properly regulated medicines should be manufactured, imported, distributed and sold in Nigeria, warning that any attempt to bypass regulatory procedures would attract decisive sanctions.

The blacklist of Onifam Laboratories marks one of the agency’s strongest recent enforcement actions and underscores its resolve to strengthen regulatory oversight, improve accountability within the pharmaceutical industry and sustain public confidence in Nigeria’s medicines regulatory framework.

Advertisement
Continue Reading

Health

What is being released to NCDC is a drop in the ocean- Senate C’ttee laments

Published

on

By

ADVERTISEMENT
Zoom Ad
ADVERTISEMENT
Zoom Ad

Poor  funding could undermine the ability of the North Central Development Commission (NCDC) to deliver on its mandate, the Senate has said, insisting that the N2.9 billion monthly allocation being released to the commission is only “a drop in the ocean” compared to its N140 billion budget  allocation for 2026.

The Chairman of the Senate Committee on the North Central Development Commission, Titus Zam, sounded the warning while briefing journalists after an interactive session between the committee and the commission’s management at the National Assembly on Tuesday.

According to him, the current monthly release would amount to less than half of the commission’s approved budget if maintained throughout the year, expressing optimism that the federal government would increase funding as the commission becomes fully operational.

“If you give someone that has a budget of N140 billion, N2.9 billion per month, in 12 months, it won’t be up to half of the entire budgetary sum,” Zam said.

Advertisement

“I suppose that is just a temporary package. When the commission finally comes to fruition, much more funds will be released. So we thank Mr President and the Executive for dropping something now, but we look forward to more.”

The lawmaker, however, assured that the Senate Committee would ensure the prudent utilisation of the funds already released by providing effective oversight and guiding the commission on areas of priority.

He urged the commission to focus its interventions on agriculture, security and rural development, stressing that the North Central region is largely agrarian and continues to face serious security challenges.

“North Central is mostly an agricultural land. We have arable land, we have good rainfall and vegetation. There is policy for agriculture. We need the department of NCDC to take agriculture very seriously.

Advertisement

“We also have a challenge of insecurity. The commission is advised to support the security forces and state governments to complement their efforts towards mitigating the tide of insecurity within the region.

“We also ask them to take rural development very seriously because we are also rural in nature,” Zam said.

Continue Reading

Health

NCDC records rise in Lassa fever cases, death toll hits 221

Published

on

By

ADVERTISEMENT
Zoom Ad
ADVERTISEMENT
Zoom Ad

The Nigeria Centre for Disease Control and Prevention (NCDC) says Nigeria recorded an increase in confirmed Lassa fever cases during epidemiological week 26 of 2026, with 31 new infections reported, up from 22 the previous week.

The new confirmed cases were recorded in Bauchi, Ondo, Taraba and Benue states, according to the latest NCDC Lassa fever situation report released by the public health agency on Friday.

The report showed that 221 deaths have been recorded cumulatively in 2026, with a Case Fatality Rate (CFR) of 24.0 per cent, higher than the 18.7 per cent reported in 2025.

It stated that 23 states had reported at least one confirmed Lassa fever case across 111 Local Government Areas, indicating the continued geographic spread of the disease nationwide in 2026.

Advertisement

According to the report, 85 per cent of all confirmed cases originated from Ondo, Bauchi, Taraba, Edo and Benue states, while the remaining 15 per cent were reported elsewhere.

The report said Ondo accounted for the highest proportion of confirmed cases at 30 per cent, followed by Bauchi with 26 per cent, Taraba with 14 per cent, Edo with nine per cent, and Benue.

It revealed that people aged between 21 and 30 years remained the most affected group, although confirmed cases ranged from one to 93 years, with a median age.

The report also showed that the male-to-female ratio among confirmed cases stood at 1:0.9, suggesting nearly equal infection rates between males and females across affected states.

Advertisement

Health authorities noted that both suspected and confirmed Lassa fever cases increased compared with the corresponding period in 2025, while one healthcare worker was infected during week 26.

The report added that the National Lassa Fever multi-partner, multi-sectoral Incident Management System remains activated to coordinate surveillance, case management, risk communication and response activities nationwide.

Continue Reading

Trending

Copyright © 2024 Naija Blitz News